Last updated: February 9, 2023
Sponsor: Centre Hospitalier Universitaire, Amiens
Overall Status: Active - Recruiting
Phase
N/A
Condition
Leukemia
Waldenstrom Macroglobulinemia
Lymphoproliferative Disorders
Treatment
N/AClinical Study ID
NCT04898647
PI2020_843_0109
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patient with WM
- Patients that may require a first-line or subsequent-line therapy
- patients who will require treatment initiation
- patients with serum monoclonal component concentration greater than 15 g/L and whowill underwent hyperviscosity assessment, even if hyperviscosity is not found and inthe absence of other treatment criteria, no treatment is finally initiated.
- Patients agreeing to give informed consent.
Exclusion
Exclusion Criteria:
- Patients with another chronic B-cell malignancy
- patients with lymphoplasmacytic proliferations
- patients with marginal zone lymphoma.
- patients with WM and histologic transformation
- Absence of informed consent.
Study Design
Total Participants: 100
Study Start date:
May 14, 2021
Estimated Completion Date:
August 31, 2024
Connect with a study center
CHU Amiens
Amiens, 80480
FranceActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.